Overview
ALLR market data
Price History
ALLR price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.78 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.53 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.77 – $2.35 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $19.4 · P/B 1.76.
Company news
Allarity Therapeutics Secures CLIA For In-House LabBenzinga · Jul 7, 2026, 12:10 PM
8-K filing — Allarity Therapeutics, Inc. (ALLR)SEC EDGAR · Jul 1, 2026, 12:05 PM
Allarity Therapeutics Receives U.S. Patent And Trademark Office Patent For Its Drug Response Predictor Companion DiagnosticBenzinga · Jun 30, 2026, 12:10 PM
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026Globenewswire Inc · Jun 18, 2026, 12:15 PM
Allarity Therapeutics To Present A Trial-In-Progress Poster At The ESMO Gynaecological Cancers Congress, June 17–19Benzinga · Jun 18, 2026, 12:15 PM
Allarity Therapeutics Q1 EPS $(0.17) Beats $(0.22) Estimate, Sales $25.000KBenzinga · May 15, 2026, 8:31 PM
PARP Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsightGlobenewswire Inc · May 7, 2026, 5:10 PM